Experience in Immunizing HIV-Infected Children against Pneumococcal Infection and Influenza

Relevance. The lethal outcomes of HIV infection are determined by secondary diseases, among which tuberculosis and pneumonia take the leading place. Vaccination is an important way to reduce and prevent the development of infectious diseases in both adults and children. Particular attention is paid to children with HIV infection, the incidence of which is much higher in comparison with children without HIV positive status. The purpose of the study was to study the effectiveness of the prevention of lower respiratory tract infections with pneumococcal and influenza vaccines in HIV-infected children. Materials & Methods. The material was data from medical records about HIV-infected children. The research method is visual using retrospective analysis. Results. Immunological indicators and the general health status of HIV-infected children were assessed during their registration with the regional AIDS center. Changes in the immunological status of patients under dynamic observation were described. The timing of vaccination was analyzed and a comparison was made with the development of bacterial diseases in HIV-infected children. Conclusions. A low incidence of bacterial infections and the absence of pneumococcal pneumonia in HIV-infected children were revealed. Vaccination against pneumococcal infection and influenza must be given to all HIV-infected children from the moment they are registered with a regional specialized medical institution.

vaccination, prevention, HIV-infected children, pneumococcal vaccine, PCV13, PPV23, influenza vaccine, children

1. Weiser JN, Ferreira DM, Paton JC. Streptococcus pneumoniae: transmission, colonization and invasion. Nat Rev Microbiol. 2018;16(6):355–367. doi:10.1038/s41579-018-0001-8.

2. Balsells E, Guillot L, Nair H, et al. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and metaanalysis. PLoS One. 2017;12(5). Published 2017 May 9. doi:10.1371/journal.pone.0177113.

3. Drijkoningen JJ, Rohde GG. Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect. 2014;20Suppl 5:45–51. doi:10.1111/1469-0691.12461.

4. Zachariah D, Manga P. HIV and invasive pneumococcal infection. Int J Cardiol. 2015;198:157–158. doi:10.1016/j.ijcard.2015.06.167.

5. PREVENAR 13: instrukcija po primeneniju lekarstvennogo preparata dlja medicinskogo primenenija: Ministerstvo Zdravoohranenija Rossijskoj Federacii. 2018 (In Russ.). Available at: http://petrovax.ru/upload/Prevenar_13_LLD_04.10.16.pdf. Accessed: 10 Okt. 2019.Merck. PNEUMOVAX 23 patient product information [Internet]. 2016. Available at: https://www.merck.com/product/usa/pi_circulars/p/pneumovax_23/pneumovax_ppi.pdf. Accessed: 10 Okt. 2019.

6. European Medicines Agency. Annex 1: summary of product characteristics (Prevenar 13) [Internet]. 2016. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001104/WC500057247.pdf.

7. Vakcinoprofilaktika pnevmokokkovoj infekcii u vzroslyh. Federal clinical guidelines. Moscow, 2018 (In Russ.).

8. Rubin LG, Levin MJ, Ljungman P, et al. IDSA clinical practice guideline for vaccination of the immunocompromised host. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2014;58(3):309–18. Epub 2014/01/15. 10.1093/cid/cit816.

9. Rukovodstvo po klinicheskoj immunologii v respiratornoj medicine. Ed.: Kostinov MP, Chuchalin AG. Moscow: Gruppa MDV, 2018(In Russ.).

10. Cohen R, Levy C, Bingen E, et al. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr. Infect. Dis. J. 2012;31(3):297–301.

11. Weinberger DM, Givon-Lavi N, Shemer-Avni Y, et al. Influence of pneumococcal vaccines and respiratory syncytial virus on alveolar pneumonia, Israel. Emerg. Infect. Dis. 2013;19(7):1084–1091.

12. Diel M, Laurenz M. Impact of pneumococcal conjugate vaccines on pneumonia among children in Germany. ESPID, 2013.

13. Tagarro A, Benito A, Sanchez A, et al. Bacteremia in Children Observation Program (BACO) Group. Bacteremic pneumonia before and after Withdrawal of 13-valent pneumococcal conjugate vaccine from a public vaccination program in Spain: a case-control study. J. Pediatr. 2016;171:111–115.

14. Grant LR, Hammitt LL, O’Brien SE, et al. Impact of the 13-valent pneumococcal conjugate vaccine on pneumococcal carriage among American Indians. Pediatr. Infect. Dis. J. 2016;35(8):907–914.

15. Desai AP, Sharma D., Crispell E.K., Baughman W, et al. Decline in pneumococcal nasopharyngeal carriage of vaccine serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine in children in Atlanta, Georgia. Pediatr. Infect. Dis. J. 2015;34(11):1168–1174.

16. Ben-Shimol S, Givon-Lavi N, Greenberg D, et al. Pneumococcal nasopharyngeal carriage in children < 5years of age visiting the pediatric emergency room in relation to PCV7 and PCV13 introduction in southern Israel. Hum. Vaccin. Immunother. 2016;12(2): 268–276.

17. Steens A, Caugant DA, Aaberge IS, et al. Decreased carriage and genetic shifts in the streptococcus pneumoniae population after changing the 7-valent to the 13-valent pneumococcal vaccine in Norway. Pediatr. Infect. Dis. J. 2015;34(8): 875–883.

18. Dzhumagaziev AA, Raysky DV, Dzhalmukhamedova EI, et al. Immunizacija Str. Pneumonia snizhaet chastotu ostryh otitov u vospitannikov doma rebenka (predvaritel’nye rezul’taty. Journal of Infectology. 2012;4(3):76–79 (In Russ.).

19. Diao WQ, Shen N, Yu PX, et al. Efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing community-acquired pneumonia among immunocompetent adults: A systematic review and meta-analysis of randomized trials. Vaccine. 2016;34(13):1496–1503. doi:10.1016/j.vaccine.2016.02.023.

20. Suzuki M, Dhoubhadel BG, Ishifuji T, et al. Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study. Lancet Infect Dis. 2017;17(3):313–321. doi:10.1016/S1473-3099(17)30049-X

21. Baranov AA, Namazova-Baranova LS, Briko NI, et al. Vakcinoprofilaktika pnevmokokkovoj infekcii u detej. Pediatric pharmacology. 2015;12(5):550–558 (In Russ.). doi: 10.15690/pf.v12i5.1457.

22. Belotserkovskaya YuG, Romanovsky AG, Styrt EA. Pnevmokokkovaja vakcina u vzroslyh snizhaet risk infekcij, vyzvannyh Streptococcus Pneumoniae. Clinical medicine. 2016;094(1):61–66 (In Russ.). DOI 10.18821/0023-2149-2016-94-1-61-66.

23. Briko NI, Feldblum IV, Bikmieva AV, et al. Vakcinoprofilaktika vzroslogo naselenija protiv pnevmokokkovoj infekcii. Antibiotics and chemotherapy. 2019;65(1–2):37–43 (In Russ.).

24. Zaitsev AE, Kurbatova EA, Egorova NB, et al. Immunologicheskie i jepidemiologicheskie aspekty immunogennosti kapsul’nogo polisaharida Streptococcus pneumoniae serotipa 3 v sostave pnevmokokkovyh vakcin. Journal of Microbiology, Epidemiology and Immunobiology. 2020;97(1):72–82 (In Russ.). DOI: https://doi.org/10.36233/0372-9311-2020-97-1-72-82.

25. Lombardi F, Belmonti S, Fabbiani M, et al. Immunogenicity and safety of the 13-valent pneumococcal conjugate Vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: a pilot, prospective controlled study [Internet]. PLoS One. 2016. Available at: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0156523. Accessed: 10 Okt. 2019.

26. Berical AC, Harris D, Dela Cruz CS, et al. Pneumococcal Vaccination Strategies. An Update and Perspective. Ann Am Thorac Soc. 2016;13(6):933–944. doi:10.1513/AnnalsATS.201511-778FR.

27. World Health Organization. Policy brief: updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: HIV treatment, interim guidance. World Health Organization [Internet]. 2018. Available at: http://www.who.int/iris/handle/10665/273632. Accessed: 13 Okt. 2019.